Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

ADRB2 gene polymorphisms may predict response to timolol and betaxolol therapy in glaucoma

Nov. 25, 2010

INCB-028050 therapy leads to clinical response in phase II trial in active RA

Nov. 25, 2010

First-in-human data presented on GPVI-Fc fusion protein revacept

Nov. 25, 2010

FG-4592 is safe and increases hemoglobin levels in CKD-related anemia

Nov. 24, 2010

First-in-human data disclosed on dual PI3K/mTOR inhibitors PF-05212384 and PF-04691502

Nov. 24, 2010

LCZ-696 is well tolerated by patients with chronic stable heart failure in phase II trial

Nov. 24, 2010

BMS-582949 shows promise to treat rheumatoid arthritis

Nov. 24, 2010

GRN-529 has antidepressant, anxiolytic and analgesic effects in vivo

Nov. 24, 2010

Phase Ia trial demonstrates safety of SGN-70 in healthy subjects

Nov. 24, 2010

EVX-001688 improves spatial memory in young and aged rats

Nov. 24, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...